Zai Lab is a patient-focused, innovative, commercial-stage, global biopharmaceutical company based in China and the U.S. We are focused on bringing best-in-class and first-in-class medicines for oncology, autoimmune disorders, infectious diseases and neurological disorders to patients in greater China and around the world.
The company was founded by Dr. Samantha Du, Chairperson and CEO, in 2014 to help address significant unmet medical needs in China and to be at the forefront of healthcare reforms in China aimed at supporting and accelerating development of innovative medicines and therapies. Zai Lab’s experienced team has secured partnerships with leading global biopharmaceutical companies, generating a broad pipeline of innovative late-stage drug candidates, four of which have now been launched in China. Based on the company’s extensive track record of execution, Zai Lab has earned the reputation as a trusted partner of choice for global biopharmaceutical companies seeking to access the Chinese market as well as to find a long-term strategic partner for global clinical development.
Zai Lab is a fully integrated biopharmaceutical company with end-to-end capabilities. Zai has internal R&D centers to advance its discovery pipeline, a strong clinical development team that currently manages more than 50 ongoing or planned clinical trials, small-molecule and large-molecule manufacturing facilities, an experienced regulatory affairs group, and a highly specialized commercial team to support marketing of innovative products.
Zai Lab has significantly expanded its global presence in recent years. The company now has its headquarters and an R&D center in Shanghai, clinical and regulatory offices in Beijing, manufacturing and R&D facilities in Suzhou, commercial offices in Hong Kong, Taiwan and Guangzhou, and U.S. offices in Menlo Park and Cambridge. As of December 2021, the Company had a global team of more than 1,900 employees.
